Company profile
Vesynta Limited
403 Forbidden
Vesynta Limited is a UK company with status active founded in 2019 based in London.
Latest accounts
Financial period: 1 Sep 2023 to 31 Aug 2024
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Confirmation Statement With No Updates
Confirmation-statementCS01 | Transaction MzUxNDM0NzcyM2FkaXF6a2N4
Published 03 Apr 2026 21:14
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Second Filing Capital Allotment Shares
CapitalRP04SH01 | Transaction MzQ0MDY0NTUxN2FkaXF6a2N4 | Paper/PDF filed
Published 30 Oct 2024 07:06
Capital Allotment Shares
CapitalSH01 | Transaction MzQxODUyOTU5OGFkaXF6a2N4 | Paper/PDF filed
Published 25 Oct 2024 12:27
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Project Checkpoint: Precision Immunotherapy via Remote Toxicity Monitoring
1 Sep 2024 to 28 Feb 2026
**Who is Vesynta?** A diagnostic enabled precision medicine company. We combine patient monitoring with clinical decision support to maximise therapeutic potential and de-risk drug treatment. **Who are we helping?** The 40% of cancer patients eligible for immunotherapy treatment **What's the challenge?** Immunotherapies are fast becoming standard of care ...
Dosologic: a precision dosing software optimising chemotherapy for children.
1 Dec 2022 to 30 Nov 2025
**Who is Vesynta?** A personalised medicine company that delivers data-guided precision dosing via rapid patient monitoring. **Who are we helping?** The 400,000 children diagnosed with cancer globally each year. **What's the challenge?** Choosing the optimal chemotherapy dose. Many factors (fat distribution/organ function/enzyme availability, etc.) affect...
Establishing a translational leader in precision medicine through knowledge transfer to develop point-of-care drug monitoring technologies
1 Mar 2021 to 29 Feb 2024
This bi-directional collaboration, offers a secondee from Newcastle University an opportunity to work with an innovative biomedical start-up, Vesynta Ltd, for the development of a novel companion monitoring tool, enabling doctors to accurately monitor anti-cancer drug-exposure in children. It will provide an immediate, simple to use, bedside measurement o...
Miniaturisation Techniques for Dose Optimisation of Chemotherapeutic Agents (miniDOC)
1 Mar 2021 to 31 Aug 2023
As an Innovation Scholar, **Anand Pallipurath Radhakrishnan (APR)**, would swiftly transition from University College London (UCL) Electrochemical Innovations Lab (EIL) to work with the host company, **Vesynta Ltd.**, marking a new knowledge exchange partnership. **The miniDOC project**, led by UCL, will be partnered by Vesynta with additional input from ...